Core Concepts
Blood-based screening for colorectal cancer is not as effective or cost-effective as established methods like colonoscopy.
Abstract
The content discusses the effectiveness and limitations of blood-based screening for colorectal cancer compared to traditional methods like colonoscopy. It includes insights from two modeling studies and an expert commentary.
Key Highlights:
- Blood tests detect circulating nucleotides associated with CRC.
- Studies analyzed effectiveness and cost-effectiveness of blood-based screening.
- Blood-based screening is not recommended to replace established methods.
- Blood tests may lead to more false positives and negatives.
- Cost-effectiveness and outcomes of blood-based screening were compared to FIT, stool DNA, and colonoscopy.
Structure:
- Introduction to Blood-Based Screening for CRC
- Expert Commentary on Blood-Based Tests
- Modeling Studies on Effectiveness and Cost-Effectiveness
- Comparing CRC Screening Methods
- Additional Considerations from AGA CRC Workshop Panel
Stats
"Without screening, the models predicted between 77 and 88 CRC cases and between 32 and 36 deaths per 1,000 individuals."
"Blood-based screening was considered cost-effective, with an additional cost of $25,600 to $43,700 per quality-adjusted life-year gained (QALYG)."
"A blood-based test at the CMS minimum reduced CRC incidence by 40% and CRC mortality by 52% versus no screening."
Quotes
"High APL sensitivity, which can result in CRC prevention, should be a top priority for screening test developers."
"Unless we have the expectation of high sensitivity and specificity, blood-based colorectal cancer tests could lead to false positive and false negative results, which are both bad for patient outcomes."